After Hours
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
UroGen Pharma Ltd is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. The current market capitalization of UroGen Pharma Ltd is $540.69M. A total of 0.71 million shares were traded on the day, compared to an average of 562.72K shares.
In the most recent transaction, Schoenberg Mark sold 859 shares of URGN for 13.08 per share on Sep 09 ’24. After the transaction, the Chief Medical Officer now owns 145,091 company shares. In a previous transaction on Sep 09 ’24, Smith Jason Drew sold 1,521 shares at 13.08 per share. URGN shares that General Counsel owns now total 25,226.
Among the insiders who bought shares, Schoenberg Mark acquired of 859 shares on Sep 09 ’24 at a per-share price of $13.23. In another insider transaction, Schoenberg Mark sold 5,153 shares at $13.08 per share on Jun 10 ’24. Company shares held by the Chief Medical Officer now total 144,284.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. In terms of 52-week highs and lows, URGN has a high of $20.70 and a low of $10.60.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information. URGN’s latest balance sheet shows that the firm has $89.14M in Cash & Short Term Investments as of fiscal 2021. There were $398.00k in debt and $22.38M in liabilities at the time. Its Book Value Per Share was $0.74, while its Total Shareholder’s Equity was $8.41M.
Analysts Opinion
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for URGN is Buy with a score of 4.71.
